Cargando…

Survival and prognostic factors in conventional G1 chondrosarcoma

BACKGROUND: Chondrosarcoma is the second most frequent malignant bone tumor. Grade I chondrosarcoma (syn.: atypical cartilaginous tumor) is classified as an intermediately and locally aggressive neoplasm and typically is treated less aggressively (i.e., by intralesional curettage). Does the data reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Fromm, Julian, Klein, Alexander, Baur-Melnyk, Andrea, Knösel, Thomas, Lindner, Lars, Birkenmaier, Christof, Roeder, Falk, Jansson, Volkmar, Dürr, Hans Roland
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724259/
https://www.ncbi.nlm.nih.gov/pubmed/31481076
http://dx.doi.org/10.1186/s12957-019-1695-4
_version_ 1783448952249516032
author Fromm, Julian
Klein, Alexander
Baur-Melnyk, Andrea
Knösel, Thomas
Lindner, Lars
Birkenmaier, Christof
Roeder, Falk
Jansson, Volkmar
Dürr, Hans Roland
author_facet Fromm, Julian
Klein, Alexander
Baur-Melnyk, Andrea
Knösel, Thomas
Lindner, Lars
Birkenmaier, Christof
Roeder, Falk
Jansson, Volkmar
Dürr, Hans Roland
author_sort Fromm, Julian
collection PubMed
description BACKGROUND: Chondrosarcoma is the second most frequent malignant bone tumor. Grade I chondrosarcoma (syn.: atypical cartilaginous tumor) is classified as an intermediately and locally aggressive neoplasm and typically is treated less aggressively (i.e., by intralesional curettage). Does the data regarding local recurrence (LR) and metastatic disease justify this? METHODS: From 1982 to 2014, 37 consecutive patients with G1 chondrosarcoma had been resected or curetted. The margin was defined as R0 (wide resection) or R1 (marginal resection). All patients were followed for evidence of local recurrence or metastatic disease. Overall and recurrence-free survival were calculated, and various potentially prognostic factors were evaluated. RESULTS: In 23 patients (62%), the tumor was widely (R0) resected, whereas in 14 patients, (38%) the resection was marginal (R1). Overall survival was 97% after 5 years, 92% after 10 years, and 67% after 20 years. Five-year local recurrence-free survival was 96%. Ten-year local recurrence-free survival was 83%. Local recurrence-free survival showed a significant correlation to margin status but no correlation to location or age. None of the patients with local recurrence died during the follow-up. One patient had metastatic disease at initial presentation, and a further five patients developed metastatic disease during follow-up. Metastatic disease proofed to be a highly significant factor for survival but was not correlated to local recurrence. CONCLUSIONS: There was no significant correlation between the outcome and the primary tumor location. Marginal resection was a risk factor for LR, but there was no significant difference in the overall survival in patients with or without LR. Metastatic disease (16%) was more common than expected from the literature and a significant predictor for poor overall survival.
format Online
Article
Text
id pubmed-6724259
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67242592019-09-10 Survival and prognostic factors in conventional G1 chondrosarcoma Fromm, Julian Klein, Alexander Baur-Melnyk, Andrea Knösel, Thomas Lindner, Lars Birkenmaier, Christof Roeder, Falk Jansson, Volkmar Dürr, Hans Roland World J Surg Oncol Research BACKGROUND: Chondrosarcoma is the second most frequent malignant bone tumor. Grade I chondrosarcoma (syn.: atypical cartilaginous tumor) is classified as an intermediately and locally aggressive neoplasm and typically is treated less aggressively (i.e., by intralesional curettage). Does the data regarding local recurrence (LR) and metastatic disease justify this? METHODS: From 1982 to 2014, 37 consecutive patients with G1 chondrosarcoma had been resected or curetted. The margin was defined as R0 (wide resection) or R1 (marginal resection). All patients were followed for evidence of local recurrence or metastatic disease. Overall and recurrence-free survival were calculated, and various potentially prognostic factors were evaluated. RESULTS: In 23 patients (62%), the tumor was widely (R0) resected, whereas in 14 patients, (38%) the resection was marginal (R1). Overall survival was 97% after 5 years, 92% after 10 years, and 67% after 20 years. Five-year local recurrence-free survival was 96%. Ten-year local recurrence-free survival was 83%. Local recurrence-free survival showed a significant correlation to margin status but no correlation to location or age. None of the patients with local recurrence died during the follow-up. One patient had metastatic disease at initial presentation, and a further five patients developed metastatic disease during follow-up. Metastatic disease proofed to be a highly significant factor for survival but was not correlated to local recurrence. CONCLUSIONS: There was no significant correlation between the outcome and the primary tumor location. Marginal resection was a risk factor for LR, but there was no significant difference in the overall survival in patients with or without LR. Metastatic disease (16%) was more common than expected from the literature and a significant predictor for poor overall survival. BioMed Central 2019-09-03 /pmc/articles/PMC6724259/ /pubmed/31481076 http://dx.doi.org/10.1186/s12957-019-1695-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Fromm, Julian
Klein, Alexander
Baur-Melnyk, Andrea
Knösel, Thomas
Lindner, Lars
Birkenmaier, Christof
Roeder, Falk
Jansson, Volkmar
Dürr, Hans Roland
Survival and prognostic factors in conventional G1 chondrosarcoma
title Survival and prognostic factors in conventional G1 chondrosarcoma
title_full Survival and prognostic factors in conventional G1 chondrosarcoma
title_fullStr Survival and prognostic factors in conventional G1 chondrosarcoma
title_full_unstemmed Survival and prognostic factors in conventional G1 chondrosarcoma
title_short Survival and prognostic factors in conventional G1 chondrosarcoma
title_sort survival and prognostic factors in conventional g1 chondrosarcoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724259/
https://www.ncbi.nlm.nih.gov/pubmed/31481076
http://dx.doi.org/10.1186/s12957-019-1695-4
work_keys_str_mv AT frommjulian survivalandprognosticfactorsinconventionalg1chondrosarcoma
AT kleinalexander survivalandprognosticfactorsinconventionalg1chondrosarcoma
AT baurmelnykandrea survivalandprognosticfactorsinconventionalg1chondrosarcoma
AT knoselthomas survivalandprognosticfactorsinconventionalg1chondrosarcoma
AT lindnerlars survivalandprognosticfactorsinconventionalg1chondrosarcoma
AT birkenmaierchristof survivalandprognosticfactorsinconventionalg1chondrosarcoma
AT roederfalk survivalandprognosticfactorsinconventionalg1chondrosarcoma
AT janssonvolkmar survivalandprognosticfactorsinconventionalg1chondrosarcoma
AT durrhansroland survivalandprognosticfactorsinconventionalg1chondrosarcoma